Ken Griffin Vor Biopharma Inc. Call Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024
SELL
$1.8 - $2.85 $2,880 - $4,560
-1,600 Reduced 47.06%
1,800 $4,000
Q4 2023

Feb 14, 2024
SELL
$1.66 - $2.63 $4,648 - $7,364
-2,800 Reduced 45.16%
3,400 $7,000
Q3 2023

Nov 14, 2023
BUY
$2.1 - $3.35 $8,190 - $13,065
3,900 Added 169.57%
6,200 $13,000
Q2 2023

Aug 14, 2023
SELL
$3.09 - $5.33 $48,513 - $83,681
-15,700 Reduced 87.22%
2,300 $7,000
Q1 2023

May 15, 2023
SELL
$4.68 - $6.96 $27,144 - $40,368
-5,800 Reduced 24.37%
18,000 $96,000
Q4 2022

Feb 14, 2023
BUY
$3.98 - $7.43 $94,724 - $176,834
23,800 New
23,800 $158,000

Others Institutions Holding VOR

# of Institutions
70
Shares Held
29M
Call Options Held
1.8K
Put Options Held
100
View Full List

About Vor Biopharma Inc.

VOR Quotes by TradingView
  • Ticker VOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,056,300
  • Market Cap $34.6M
  • Description
  • Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...
More about VOR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email